IDRA-21

1990s benzothiadiazide ampakine that potently slows AMPA receptor desensitization in vitro and improves memory in animals — but has never been tested in humans, has no GMP supply, and is structurally adjacent to compounds that lower seizure threshold. The modern equivalent that Dylan should consider instead is TAK-653 (clinical-trial grade ampakine with human safety data). IDRA-21 is research-chemistry trivia, not a serious option.

IDRA-21 is a benzothiadiazide that binds at an allosteric site on the AMPA-type ionotropic glutamate receptor distinct from the glutamate-binding orthosteric site. Glutamate still has to bind for the receptor to open; IDRA-21 just changes the receptor's behavior once it does:

• Slows desensitization: Normal AMPA receptors desensitize within ~10 ms of glutamate binding, terminating the postsynaptic current. IDRA-21 dramatically extends that window, so each glutamate release event produces a larger and longer Na+/K+ flux through the receptor.
• Net effect: Stronger glutamatergic transmission at any synapse where AMPA receptors carry the signal — most prominent in hippocampus and cortex, exactly the substrates of explicit memory and working memory.
• Downstream: Sustained AMPA activity drives Ca2+-permeable currents and BDNF transcription via CaMKII/CREB. This is the hypothesized basis for ampakine pro-cognitive and neurotrophic effects.

Ampakines split into two classes by binding site:

• Type I ("low-impact"): e.g., CX-516, CX-717. Slow deactivation more than desensitization. Subtler EEG signature, lower seizure liability.
• Type II ("high-impact"): e.g., IDRA-21, cyclothiazide. Block desensitization aggressively. Larger pro-cognitive effect in animals BUT higher seizure liability — cyclothiazide is in fact used to induce epileptiform activity in slice preparations.

IDRA-21 sits in the high-impact camp — that is the source of its appeal AND its risk.